Dr. Dan Skovronsky is the chief scientific and product officer of Eli Lilly and Company and president of Lilly Research Laboratories. In this combined role, Dan heads research and development at Lilly while also carrying global responsibility for commercial products across Lilly Cardiometabolic Health, Lilly Immunology, and Lilly Neuroscience. The span of this role reflects Lilly’s commitment to the full spectrum of medicine development, from initial discovery through successful commercialization, recognizing that innovation isn’t finished when a molecule becomes a medicine, it’s only finished when patients use that medicine to improve their health.

Dr. Skovronsky joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals Inc., where he had been CEO since founding the company in 2004. At Lilly, Dr. Skovronsky has held various roles, including vice president, tailored therapeutics; vice president, diabetes research; and senior vice president, clinical and product development.

Dr. Skovronsky completed his residency training in pathology and fellowship training in neuropathology at the Hospital of the University of Pennsylvania. He received his M.D. from the Perelman School of Medicine, University of Pennsylvania, in 2001 and his Ph.D. in neuroscience from University of Pennsylvania in 2000. He earned a Bachelor of Science in molecular biophysics and biochemistry from Yale University in 1994.